Blood pressure treatment includes risk factor modification.
نویسندگان
چکیده
منابع مشابه
Transient ischemic attack: Part II. Risk factor modification and treatment.
Interventions following a transient ischemic attack are aimed at preventing a future episode or stroke. Hypertension, current smoking, obesity, physical inactivity, diabetes mellitus, and dyslipidemia are all well-known risk factors, and controlling these factors can have dramatic effects on transient ischemic attack and stroke risk. For patients presenting within 48 hours of resolution of tran...
متن کاملAlcohol consumption as a risk factor for high blood pressure. Munich Blood Pressure Study.
The Munich Blood Pressure Study (MBS), a 1980-81 cross-sectional study (with follow-up) of a random sample of 3198 Munich citizens aged 30-69 years (response rate 69%), revealed hypertensive blood pressure (BP) values in 17.7% of men and 10.7% of women (WHO criteria). One of the main goals of the MBS was to search for social, behavioral, and environmental risk factors for hypertension. The rela...
متن کاملFocus on blood pressure as a major risk factor
1866 www.thelancet.com Vol 383 May 31, 2014 The main ris k factor for disease and premature death worldwide is high blood pressure. The associations between blood pressure and fatal coronary artery disease and fatal stroke have been well demonstrated. However, little evidence exists from contemporary clinical practice on the associations between blood pressure and morbidity and mortality from s...
متن کاملResidual Cardiovascular Risk in Individuals on Blood Pressure–Lowering Treatment
BACKGROUND Hypertensive individuals on blood pressure (BP)-lowering treatment with BP in the normal or high-normal range have higher cardiovascular risk than untreated persons with usual BP in the same range. This residual risk (relative and absolute) is not well quantified and may be attributable in part to the higher burden of subclinical disease in treated individuals. METHODS AND RESULTS ...
متن کاملEndothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
Irbesartan, an angiotensin II type 1 receptor antagonist, is approved as monotherapy, or in combination with other drugs, for the treatment of hypertension in many countries worldwide. Data in the literature suggest that irbesartan is effective for reducing blood pressure over a 24-hour period with once-daily administration, and slows the progression of renal disease in patients with hypertensi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hypertension
سال: 1987
ISSN: 0194-911X,1524-4563
DOI: 10.1161/01.hyp.9.4.420